Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
64Cu-SAR-BBN PET/CT in PSMA-negative biochemical recurrence of prostate cancer
NCT05407311Phase 2Completed
- Sponsor
- Clarity Pharmaceuticals
- Start
- Sep 2022
- Primary completion
- May 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of 64Cu-SAR-bombesin, sponsored by Clarity Pharmaceuticals. Started Sep 2022; status: completed.
02
Drugs
64Cu-SAR-bombesin
Beyond the preview
Go deeper on NCT05407311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05407311.